CapsoVision to Participate in Upcoming Investor Conferences
Globe Newswire (Thu, 3-Sep 4:05 PM ET)
CapsoVision Reports Second Quarter 2026 Financial Results
Globe Newswire (Thu, 13-Aug 4:05 PM ET)
CapsoVision Announces International Launch of AI Highlights
Globe Newswire (Mon, 3-Aug 4:30 PM ET)
CapsoVision to Release Second Quarter 2026 Financial Results on August 13, 2026
Globe Newswire (Thu, 30-Jul 4:05 PM ET)
CapsoVision Appoints Gastroenterology Leader David S. Shields, M.D., to Board of Directors
Globe Newswire (Thu, 2-Jul 4:05 PM ET)
Market Chameleon (Mon, 23-Mar 7:43 AM ET)
CapsoVision Inc is a commercial-stage medical technology enterprise that innovates, manufactures, and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal (GI) system. The company's core technology platform is an orally ingestible capsule including multiple cameras facilitating 360-degree imaging, light-emitting diodes for measurement, onboard memory storage, and battery life permitting recording and onboard storage of video images. CapsoVision's products consist of the on-market CapsoCam Plus, directed at the small intestines, and the in-development CapsoColon 3D, directed at the large intestines. Geographically, the company generates the majority of its revenue from the United States.
Capsovision trades on the NASDAQ stock market under the symbol CV.
As of September 25, 2026, CV stock price climbed to $6.65 with 179,140 million shares trading.
CV has a beta of -1.70, meaning it tends to be less sensitive to market movements. CV has a correlation of 0.04 to the broad based SPY ETF.
CV has a market cap of $353.85 million. This is considered a Small Cap stock.
Last quarter Capsovision reported $4 million in Revenue and -$.15 earnings per share. This fell short of revenue expectation by $-170,000 and missed earnings estimates by -$.02.
The top ETF exchange traded funds that CV belongs to (by Net Assets): VTI, IWM, IWO, VTWO, IWC.
CV has outperformed the market in the last year with a return of +46.2%, while the SPY ETF gained +18.4%. However, in the most recent history, CV shares have underperformed the stock market with its stock returning -4.9% in the last 3 month period and +0.8% for the last 2 week period, while SPY has returned +5.3% and +1.2%, respectively.
CV support price is $5.86 and resistance is $6.48 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CV shares will trade within this expected range on the day.